Resource Library

The first two videos on this page are intended as a training supplement only for the Eversense CGM System. They are not a substitute for the certification training. To learn more about how to become a provider, visit the Become A Provider page.

Watch the Video

EVERSENSE ANIMATED INSERTION AND REMOVAL VIDEO
Quickly learn how to place a new Eversense Sensor and remove a previous sensor in this 10 minute animated video




Watch the Video >
Watch the Video

EVERSENSE INSERTION AND REMOVAL TRAINING VIDEO
Learn how to place a new Eversense Sensor and remove a previous sensor. This video gives you step-by-step guidance, along with best practices for placement, closure and removal techniques.



Watch the Video >
Watch the Video

SETTING UP A STERILE FIELD
Watch this video to learn how to quickly and efficiently set up the required sterile field for the insertion or removal of the Eversense sensor. Note: Some insertion tools will have a red locking tab that needs to be removed prior utilizing the insertion tool.



Watch the Video >
Watch the Video

PUTTING ON STERILE GLOVES
This instructional video demonstrates the steps necessary to put on sterile gloves prior to sensor insertion or removal.



Watch the Video >
Download PDF

PATIENT TAKE HOME INSTRUCTIONS
This pdf with helpful take-home instructions and tips will be useful for your patient. Download it here and provide to your patient after the sensor insertion.



Download PDF >
Launch Interactive Module

EVERSENSE PATIENT EDUCATION TRAINING





Launch Interactive Module >
Download PDF

EVERSENSE DATA MANAGEMENT SYSTEM (DMS) PRO
Our comprehensive, easy-to-use data management system allows patients to share their data with you.




Download PDF >
Download PDF

SAMPLE OFFICE PROCEDURE CONSENT FORM
If your practice does not have a procedure consent form, here's a sample you can use.





Download PDF >
Download the Clinical Study

THE PRECISE II (U.S.) TRIAL - 2016
The second study (Precise II) included 90 participants with Type 1 and Type 2 diabetes. It was performed in the United States and demonstrated the efficacy and safety of the Eversense CG System during 90 days of continuous sensor wear.



Download the Clinical Study >
Download the Clinical Study

ACCEPTABILITY OF IMPLANTABLE CGM (EUROPE) - 2017
This European study included 51 participants with Type 1 and Type 2 diabetes. It showed that the Eversense CGM with under-the-skin sensor was widely accepted by users and favorably evaluated by a high percentage of participants in the study.





Download the Clinical Study >
Download the Clinical Study

THE PRECISION TRIAL (U.S) - 2018
This 90-day trial included 35 adults with Type 1 and Type 2 diabetes and was designed to provide additional data on the Eversense CGM system with regard to accuracy and safety. Findings confirmed the accuracy and safety of the implantable sensor throughout the sensor life and showed a slight increase in accuracy in the very low hypoglycemic range.



Download the Clinical Study >
Download the Clinical Study

INTERFERENCE ASSESSMENT OF VARIOUS ENDOGENOUS AND EXOGENOUS SUBSTANCES ON THE PERFORMANCE OF THE EVERSENSE LONG-TERM IMPLANTABLE CONTINUOUS GLUCOSE MONITORING SYSTEM
Learn which prescription drugs interfere with the functioning of the Eversense sensor in this report from the National Center for Biotechnology Information (NCBI.)



Download the Clinical Study >

 

Disclaimer

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For safety information click here.

Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.